Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.

Saved in:
Bibliographic Details
Title: Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.
Authors: Yan Z; Department of Pathology, Duke University School of Medicine, Durham, NC.; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC., Han Z; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC., Wang Y; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC., Beus M; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC., Zhang Y; Department of Hematology and Medical Oncology, Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, GA., Picado A; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC., Wells CI; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC., Wu J; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC., Weidenhammer LB; Department of Pathology, Duke University School of Medicine, Durham, NC., Pires KM; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, The University of Utah, Salt Lake City, UT., Leibold EA; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, The University of Utah, Salt Lake City, UT., Liu L; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC., Gooden DM; Small Molecule Synthesis Facility, Department of Chemistry, Duke University, Durham, NC., Spasojevic I; Pharmacokinetics and Pharmacodynamics Core, Duke Cancer Institute, and Department of Medicine, Duke University Medical Center, Durham, NC., Soderblom EJ; Proteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, NC., Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC., Boise LH; Department of Hematology and Medical Oncology, Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, GA., Willson TM; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC., Nikiforov MA; Department of Pathology, Duke University School of Medicine, Durham, NC.; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC.
Source: Blood [Blood] 2026 Jan 01; Vol. 147 (1), pp. 48-60.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025029950